Market Overview

Novartis Vaccine Bexsero Approved in Australia


Novartis (NYSE: NVS) announced today that the Australian Therapeutic Goods Administration (TGA) has added Bexsero®, a multi-component Meningococcal B (MenB) vaccine (recombinant, adsorbed) suspension for injection 0.5 ml pre-filled syringe, to the Australian Register of Therapeutic Goods (ARTG) for use in individuals from two months of age and older[6]. Bexsero is the first and only broad coverage vaccine to help protect all age groups against MenB disease, including infants who are at the greatest risk of infection[7],[8].Across Australia, approximately 85 percent of all meningococcal disease and

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (NVS)

View Comments and Join the Discussion!

Partner Center